Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab

被引：0
|
作者：
Van Asten, K. [1 ]
Jongen, L. [1 ]
Beuselinck, B. [2 ]
Laenen, A. [3 ]
Wildiers, H. [2 ]
Poppe, A. [4 ]
Floriss, G. [5 ]
Christiaens, M. [6 ]
Neven, P. [4 ]
机构：
[1] Katholieke Univ Leuven, Oncol, Leuven, Belgium
[2] UZ Leuven, Gen Med Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium
[4] UZ Leuven, Gynaecol & Obstet, Leuven, Belgium
[5] UZ Leuven, Imaging & Pathol, Leuven, Belgium
[6] UZ Leuven, Surg, Leuven, Belgium
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P270
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [1] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] POPULATION BASED OUTCOME OF HER2 POSITIVE EARLY BREAST CANCER IN TRASTUZUMAB ERA
    Matos, E.
    Kuhar, C. Grasic
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 113
  • [3] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [4] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [6] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [7] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [8] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
  • [9] Impact of HER2 Copy Number in IHC HER2 2+/FISH Positive Breast Cancer on Outcome of Adjuvant Trastuzumab Treatment
    Borley, A.
    Mercer, T.
    Morgan, M.
    Barrett-Lee, P.
    Jasani, B.
    JOURNAL OF PATHOLOGY, 2013, 231 : 19 - 19
  • [10] HER2 Expression Impacts Trastuzumab Deruxtecan Efficacy in Breast Cancer
    不详
    CANCER DISCOVERY, 2023, 13 (10) : 2117 - 2117
12345